Rocket Lab RKLB stock prediction: $293 bull, $111 base, $76…

Every Rocket Lab (RKLB) price prediction hinges on the same event: the first launch of the Neutron rocket, penciled in for the fourth quarter of 2026. That framing is wrong. The man building the rocket says so himself. “Neutron is certainly mission enabling, but it’s not mission critical,” chief executive Peter Beck told investors this year. The company the market prices as a binary bet on one launch date is, on the numbers, a vertically integrated space-infrastructure business that happens to also launch rockets. RKLB closed 6 August 2026 at $75.67 — up 29.1% from its 29 July close of $58.60, and after touching $80.19 intraday it still finished below the $76 bear case the Street set for it. Morgan Stanley’s $293 bull case still stands against a $105 base case from the same desk. That is not an argument about Neutron. It is an argument about what kind of company you think you are buying.

Updated 7 August 2026: refreshed for the 6 August close of $75.67, the intraday break above $76 that did not hold, the $397 million Space Force Flatellite award, the new iQPS multi-launch deal, and the Q2 earnings setup for Monday 10 August. All prices verified at the 6 August close.

July delivered the bear case without the bear thesis. The stock ran from $93.09 to $58.60 in four weeks — straight through the $76 Street-low target — and then rebounded hard: up 29.1% from that low close, finishing at $75.67 on 6 August, per StockAnalysis. None of the bear’s stated conditions ever triggered. Neutron has not slipped and the core business has not wobbled. The pressure came from financing and dilution questions around the $8 billion Iridium acquisition announced 29 June, a rotation out of space names, insider selling and the broader tech washout — and even a new Space Force award failed to halt the selloff, per Benzinga. The Street never followed the price down: the average 12-month target across 18 analysts sits at $111.31, per StockAnalysis — 47.1% above spot — and the second-quarter report lands on Monday 10 August 2026.

The number nobody is framing correctly: $76 is now the ceiling

Here is the synthesis neither the bulls nor the bears have stated. The $76 Street-low target was supposed to be the floor — the worst case, the level that only broke if Neutron slipped and the core business cracked. Neither happened, and RKLB went through it anyway. It has now spent two weeks climbing back, and on 6 August it finally traded through the line, printing an intraday high of $80.19 — the first time above $76 since the July break — before giving all of it back to close at $75.67, still 0.4% underneath. A level built as a floor has now rejected the stock once on an intraday basis. That is the cleanest possible statement of the setup going into Monday.

The 6 August session is worth reading closely on its own. A $72.30 to $80.19 range on a day that closed up just 1.14% is a 10.4% swing from low to high with almost nothing to show for it — the signature of a stock where buyers and sellers disagree violently about a specific level rather than about direction. The disagreement is $76.

The options market echoes that, with a caveat worth stating plainly. TipRanks’ options tool put the implied move around the 10 August print near 17% in either direction, against what it calculated as a 10.4% average post-earnings move over the past four quarters. We were not able to corroborate that figure against a second desk before publication, and implied-move readings diverge materially depending on whether they are built from a straddle or a strangle, which expiry is used, and when they were measured — so treat 17% as one provider’s read rather than the market’s settled view. Taken at face value on a $75.67 spot, it would imply a band of roughly $62.80 to $88.55, which brackets $76 almost symmetrically. The direction of the signal is what matters more than the decimal: premiums are pricing an outsized move, and the contested level sits in the middle of it.

Key Rocket Lab (RKLB) facts and figures

• Spot: $75.67 at the 6 August 2026 close, up $0.85 (+1.14%) from a $74.82 previous close, in a $72.30–$80.19 day range. Market capitalisation $45.26 billion — StockAnalysis
• 52-week range: $37.57 – $151.00. The stock is 49.9% below its high and 101.4% above its low — StockAnalysis
• The rebound: +29.1% from the $58.60 close on 29 July, but still 0.4% below the $76 Street-low target after an $80.19 intraday high on 6 August
• New: $397 million Space Force award. On 4 August Rocket Lab was awarded a $397 million contract to develop, launch and operate Flatellites for the U.S. Space Force’s Space-Based Airborne Moving Target Indicator (SB-AMTI) programme, under the Portfolio Acquisition Executive for Space-Based Sensing and Targeting — Rocket Lab Investor Relations
• New: iQPS multi-launch deal. A 30 July agreement adds three dedicated Electron missions for Japan’s iQPS to deploy its QPS-SAR Earth-observation constellation; Rocket Lab has since flown its 92nd Electron mission for the same customer — Benzinga
• Q2 2026 earnings: Monday 10 August 2026, after the close. Consensus: a loss of $0.06 per share (versus $0.13 a year ago) on revenue of about $231.62 million, up roughly 60% year over year — TipRanks
• Q1 2026 actuals: record revenue $200.35 million, net loss narrowing to $45.02 million — Rocket Lab, May 2026
• Segment split: Space Systems $136.7M (68% of revenue) vs Launch $63.7M — CNBC
• Contracted backlog: more than $2.20 billion, with 70+ contracted missions — Rocket Lab Q1 2026
• Neutron debut: targeted for Q4 2026, “on track” per management — Spaceflight Now
• Analyst targets: Street average $111.31 across 18 analysts (Buy), median $117.50, published range $64 to $150; Morgan Stanley base case $105 and bull-case scenario $293, raised from $185; Citizens $130; Piper Sandler $83 — StockAnalysis and 24/7 Wall St.

The $397 million award changes what Monday’s call is about

The Space Force contract announced on 4 August is the most consequential thing to happen to Rocket Lab since the Iridium agreement, and it is not primarily a launch contract. Under the SB-AMTI award, Rocket Lab will develop, launch and operate Flatellites — a flat-panel satellite design built for large constellations, carrying space-based sensors and high-bandwidth, low-latency communications links — for a programme intended to detect and track airborne threats in real time.

Read the verbs. “Operate” is the one that matters. A launch contract pays once per flight; building, flying and then running a constellation for a government customer is the recurring, higher-margin end of the business, and it lands squarely in Space Systems rather than Launch. That is the same direction of travel as the Iridium deal, and it is why the $397 million figure understates the significance: it is evidence that the U.S. government is willing to buy Rocket Lab as a space-services prime, not just as a ride to orbit.

The practical consequence for Monday is that the release now has a specific thing to confirm. Investors will want to know how much of the $397 million lands in backlog this quarter, how it is phased, and whether management frames it as Space Systems revenue. The iQPS agreement signed 30 July — three more dedicated Electron missions for the QPS-SAR constellation, on top of a cadence that has now reached 92 Electron flights — is the smaller but equally telling data point: the legacy small-launch business is still winning repeat customers while the constellation business scales.

What Rocket Lab actually is, and why the stock is so volatile

Rocket Lab is best understood as two businesses stapled together. The first, and the one that made its name, is Launch: the small Electron rocket, with more than 90 flights behind it, and the larger, reusable Neutron now in development. The second, and the larger by revenue, is Space Systems: satellites, spacecraft, solar panels, flight software, and components that Rocket Lab sells to other operators and increasingly uses to build and fly its own constellations. The $8 billion agreement to acquire satellite operator Iridium pushes the company further down the “own the whole stack” path — from launching other people’s payloads to owning the payloads, the satellites, and the recurring service revenue underneath them.

Think of it as the difference between a trucking company and a logistics empire. Anyone can run a truck; the durable margins sit in owning the network, the depots, and the contracts. Rocket Lab’s launch business is the truck — visible, dramatic, and cyclical. Space Systems, the Iridium deal and now the SB-AMTI award are the network. That is why the record Q1 mattered more for the backlog line than the revenue line: contracted backlog above $2.2 billion is forward revenue the market can underwrite, and it grew because Rocket Lab closed what it called the largest launch contract in its history, a bulk purchase of Neutron and Electron flights from an undisclosed customer. Retail traders have noticed the shift too, which is why brokers are broadening access, as we covered when Fortrade added AI, space, and networking stocks to meet demand moving beyond the mega-caps.

Beck was characteristically blunt about where the constraint is not: “Demand is just not one of [the things I worry about],” he said on the earnings call. “The backlog is super healthy for a number of years.”

The SpaceX effect: RKLB is now trading on someone else’s disclosure

Something structural changed in the last fortnight, and it has nothing to do with Rocket Lab’s operations. SpaceX is now a public company, and it filed its first earnings report as one on 4 August. That report — alongside the Space Force award the same day — is the proximate cause of the rally that carried RKLB back through $76 intraday.

The read-through is more interesting than the bounce. SpaceX’s space segment generated $619 million of revenue in the first quarter of 2026, per CNBC’s earnings coverage. Rocket Lab’s consensus for the June quarter is $231.62 million. Put those side by side and Rocket Lab is running at roughly 37% of the revenue of SpaceX’s space business — a far smaller gap than the “SpaceX versus everyone” narrative implies, and the arithmetic behind Morgan Stanley’s decision to label Rocket Lab an emerging “mini-SpaceX” when it lifted its bull case to $293 from $185.

But the same filing carries a warning. SpaceX’s growth is no longer really coming from space: its AI revenue climbed 213% quarter over quarter to $2.6 billion, dwarfing the space segment entirely. The listed comparable that just re-rated the whole sector is increasingly an AI infrastructure company. Investors buying RKLB as a SpaceX proxy are buying the part of SpaceX that is growing slowest. We unpack the other side of that trade in our SpaceX SPCX stock prediction.

The bull case: a $293 scenario built on backlog, not hope

The bullish argument for RKLB is not a moon-shot on Neutron; it is a compounding-backlog story with a launch-cadence kicker. Start with the demand signal. Selling more launches in a single quarter than in an entire prior year, lifting backlog past $2.2 billion, and then adding a $397 million government constellation programme tells you the order book is filling faster than the company can fly. Add the Space Systems mix — roughly two-thirds of revenue from higher-visibility, less binary work — and you have a business whose valuation does not live or die on one launch window.

Layer Neutron on top as optionality. Neutron is a reusable medium-lift rocket aimed squarely at the market SpaceX’s Falcon 9 dominates. If it flies and proves reusable, Rocket Lab graduates from the small-satellite niche into the constellation-deployment big leagues — the highest-volume, highest-value segment of the launch market. That is the leg that justifies Morgan Stanley’s $293 bull case: not the base outcome, but the scenario where Neutron converts backlog into a recurring, high-margin cadence. It is worth being precise about what that number is — Morgan Stanley’s base case is $105, barely below the Street average, and it reiterated an Overweight rating alongside both. The $293 is the tail, not the forecast, and the desk itself conditions it on Neutron debuting on time, Iridium proving accretive, and major Golden Dome awards converting into signed dollars. The same “picks-and-shovels plus optionality” logic underpins the AI-infrastructure names we mapped in our Nebius (NBIS) price prediction, where the market pays up for owning the rails of a structural buildout.

There is also a defense pillar the momentum crowd underweights — and the SB-AMTI award is the strongest evidence for it yet. Rocket Lab flagged growing national-security and defense demand alongside the commercial backlog in Q1, with Beck describing overall demand as “super healthy” as defense and Neutron orders build, per Yahoo Finance. Government work tends to be stickier and higher-margin than commercial launch, and it leans on Rocket Lab’s proven Electron vehicle — now past 90 successful flights — rather than on the unproven Neutron. That diversification is precisely what a launch-only framing of the stock misses: the backlog is not one bet, it is several.

Beck framed the reusability challenge — the crux of the bull case — with an engineer’s candor: “If we just had to go up, it’s super easy, we’d be in orbit by now. But the reality is, it’s just as important to go up as it is to come back down and be reusable again.” Reusability is what turns a rocket from a cost center into a margin machine, and it is the single technical hurdle that gates the upside. Investors comfortable with that framing tend to view RKLB the way they view other high-beta buildout stories, such as the one in our Nvidia price prediction.

RKLB 12-month analyst targets: low, average, high

With RKLB at $75.67, the $111.31 average target implies 47.1% upside — a spread that opened because the price collapsed while the targets held, after analysts had already ridden the stock to a $151.00 all-time high in May 2026. The dispersion is enormous: the published range runs from $64 to $150 even before Morgan Stanley’s $293 tail scenario. Piper Sandler’s Alexander Potter carries $83, Citizens’ Trevor Walsh carries $130. Those two are not disagreeing about a discount rate; they are modelling different companies.

Scenario	Level	vs $75.67 spot	Anchor and what has to be true
Bear	$64	−15.4%	Lowest published 12-month target. Neutron slips into 2027, the Iridium financing dilutes, and the market goes back to pricing RKLB as a loss-making launch company. Note this still sits above the $58.60 July panic low.
Base	$111.31	+47.1%	The 18-analyst average, with Morgan Stanley’s own base case at $105 just underneath it. Space Systems keeps compounding, the $397 million SB-AMTI programme converts into backlog, and Neutron stays on its Q4 schedule without needing to fly yet.
Bull	$150	+98.2%	Highest published 12-month target, effectively a retest of the $151.00 all-time high. Requires Neutron to debut on time and the defense pipeline to keep converting. Morgan Stanley’s $293 sits beyond this as a multi-condition scenario, not a 12-month forecast.

The near-term contested level, $76, sits between the spot price and all three of those anchors — which is why Monday matters more for sentiment than for valuation. Reclaiming and holding it confirms that July was a sentiment event; failing there again keeps the stock range-bound in the $60s and low $70s regardless of what the targets say.

The bear case and the risks the momentum crowd ignores

The case for $64 is not frivolous. Start with profitability: Rocket Lab is still loss-making, posting a $45.02 million net loss in Q1 2026 even at record revenue, and consensus expects another loss — $0.06 a share — for the June quarter. A company burning cash while pouring capital into Neutron development and an $8 billion acquisition is, by definition, dependent on capital markets staying friendly. Any tightening of financing conditions raises the cost of that ambition.

Then there is the Neutron timeline itself. Beck says Q4 2026 is “on track,” but that hinges on the Archimedes engine surviving what he described as a battery of “nasty” qualification tests, per Stocktwits. Rocket development slips; it is the base rate of the industry, not the exception. A push into 2027 would not break the thesis, but it would deflate the momentum premium that carried RKLB to $151. Add the volatility already seen around the Iridium announcement, the integration risk of absorbing a satellite operator, and rising competition — SpaceX’s Falcon 9 incumbency, plus a field of new launch entrants — and the bear’s downside math is coherent. The stock is priced for execution; any stumble compresses the multiple fast.

The Space Force award cuts both ways too. Developing, launching and operating a constellation is a heavier commitment than flying someone else’s satellites: it consumes engineering capacity at the same moment Neutron needs it most. A programme that adds recurring revenue in 2027 can still add execution risk in 2026.

Crucially, Beck’s own framing is a double-edged sword. Telling investors Neutron is “not mission critical” reassures long-term holders — but it also concedes that the catalyst the momentum crowd is trading is not, by the CEO’s own account, the thing that matters most. That gap between the narrative price and the operational reality is exactly where sharp corrections live. For a comparable high-multiple name that just beat expectations and fell anyway, see our Nvidia bull and bear cases.

What happens next: three scenarios for RKLB

First, 10 August is a referendum on $76, not on Neutron. The quarter will not tell you whether the Archimedes engine works. It will tell you whether Space Systems is still compounding, whether backlog is still climbing, and how the $397 million SB-AMTI programme is being booked. Watch the backlog figure and the Space Systems revenue line above everything else on the release.

Second, Neutron remains the re-rating switch, and it is binary. A successful, on-time Q4 2026 debut — especially a clean demonstration of reusability — is the event that opens the path toward the triple-digit bull targets, because it converts Rocket Lab from a small-launch specialist into a Falcon 9 challenger. A slip into 2027 does the opposite: it does not break the company, but it drains the premium and likely marks time in the $60s and $70s.

Third, the twelve-month base case clusters near the $111.31 average, with the tails doing the real work. Reaching Morgan Stanley’s $293 still requires Neutron to fly and reusability to prove out on schedule — and it is worth repeating that the same desk’s base case is $105, which is where the honest centre of gravity sits. Between those poles, RKLB remains what it has quietly become: a space-infrastructure compounder wearing a rocket company’s volatility. Investors should size it as the high-beta position it is, watch the backlog more closely than the launch calendar, and remember that this is analysis, not investment advice.

Quick Take

Frequently asked questions

What is the Rocket Lab (RKLB) price target for 2026?

Analyst 12-month targets on Rocket Lab average $111.31 across 18 analysts with a consensus Buy rating, per StockAnalysis — implying 47.1% upside from the 6 August close of $75.67. The median is $117.50 and the published range runs from $64 to $150, with Piper Sandler at $83 and Citizens at $130. Morgan Stanley carries a $105 base case and a separate $293 bull-case scenario.

What is Rocket Lab’s $397 million Space Force contract?

Announced on 4 August 2026, it is an award under the U.S. Space Force’s Space-Based Airborne Moving Target Indicator (SB-AMTI) programme, run by the Portfolio Acquisition Executive for Space-Based Sensing and Targeting. Rocket Lab will develop, launch and operate multiple Flatellites — flat-panel satellites designed for large constellations, carrying space-based sensors and high-bandwidth, low-latency communications links — for a system intended to detect and track airborne threats in real time. The “operate” element is what makes it a Space Systems contract rather than a launch contract.

Can Rocket Lab stock reach $293?

Morgan Stanley’s $293 is a bull-case scenario, not a base target — the same desk’s base case is $105 and the highest published 12-month target from any analyst is $150. Reaching $293 would require Rocket Lab’s Neutron rocket to launch on schedule in Q4 2026 and prove reusable, the Iridium acquisition to prove accretive, and major defense awards to convert into signed contracts. Without those, the stock is more likely to trade near the $105–$111 consensus zone.

What happened to Rocket Lab’s $76 bear case?

RKLB fell straight through it in July, hitting $58.60 on 29 July without any of the bear’s stated conditions being met — Neutron did not slip and the core business did not wobble. The selloff was driven by dilution concerns around the $8 billion Iridium deal, sector rotation and insider selling. The stock has since rebounded 29.1%, and on 6 August it traded as high as $80.19 before closing at $75.67 — still 0.4% below that $76 line, which is now acting as resistance rather than support.

When does Rocket Lab report Q2 2026 earnings?

Monday 10 August 2026, after the close. Consensus expects a loss of $0.06 per share, narrowed from a $0.13 loss a year earlier, on revenue of roughly $231.62 million — about 60% growth year over year, per TipRanks. Options premiums have expanded into the print; TipRanks’ options tool put the implied move near 17% in either direction, though that figure is a single provider’s calculation and implied-move readings vary materially by methodology and expiry.

Why is Rocket Lab stock so volatile?

RKLB behaves like a high-beta bet on a single catalyst — the Neutron debut — layered on a still-loss-making balance sheet. It hit an all-time high of $151.00 in May 2026 before selling off around the $8 billion Iridium acquisition, then fell to $58.60 by late July. Because the price embeds execution expectations, any news on Neutron timing, engine testing, defense awards or the acquisition moves the stock sharply. The 6 August session alone spanned $72.30 to $80.19.

Is Rocket Lab profitable?

Not yet. Rocket Lab reported a net loss of $45.02 million in Q1 2026, even as revenue hit a record $200.35 million, and analysts expect a further loss in Q2. The company is investing heavily in Neutron development and the Iridium acquisition. Management points to expanding backlog and Space Systems growth as the path to profitability, but free cash flow remains negative during the buildout.

How does Rocket Lab compare to SpaceX now that SpaceX is public?

SpaceX’s space segment generated $619 million in Q1 2026 revenue against Rocket Lab’s $231.62 million consensus for Q2 — putting Rocket Lab at roughly 37% of its larger rival’s space-segment scale. That comparison is what led Morgan Stanley to describe Rocket Lab as an emerging “mini-SpaceX.” The caveat is that SpaceX’s growth is now driven by AI and connectivity revenue, not launch, so the proxy is an imperfect one.

What is more important for Rocket Lab: Neutron or Space Systems?

By revenue, Space Systems is larger — $136.7 million versus $63.7 million for Launch in Q1 2026 — and CEO Peter Beck has called Neutron “mission enabling, but not mission critical.” Space Systems, the Iridium deal and the new SB-AMTI constellation award drive near-term fundamentals, while Neutron represents the upside optionality that could re-rate the stock toward bull-case targets.

Sources: price, market-cap and 52-week range data from StockAnalysis (6 August 2026 close, 4:00 PM EDT); analyst targets from StockAnalysis, S&P Global and 24/7 Wall St.; the SB-AMTI award from Rocket Lab Investor Relations; the iQPS agreement and 92nd Electron mission from Benzinga; earnings date, consensus estimates and the implied-move calculation from TipRanks; Q1 2026 actuals from Rocket Lab Investor Relations; SpaceX segment data from CNBC.

This article is for information purposes only and is not financial advice. FinanceFeeds does not recommend buying or selling any security. Options-implied moves describe market pricing, not predictions, and space-sector equities are highly volatile around earnings. Always do your own research and consider consulting a licensed financial adviser.